ALLINA HEALTH LABORATORY

To: Allina Health Laboratory outreach clients

From: Allina Health Laboratory outreach services

Date: November 21, 2023

Re: New Myeloid Leukemia Next Generation Sequencing (NGS) panel

Quick Reference

Beginning November 21, 2023, Allina Health Laboratory will start offering a Myeloid Leukemia Next Generation Sequencing (NGS) panel.

Details

Effective November 21, 2023, a Myeloid Leukemia Next Generation Sequencing (NGS) panel will be available to be performed at Allina Health Laboratory.

This Myeloid NGS panel includes 71 genes. The panel consists of both a DNA component designed to detect mutations as well as an RNA component designed to detect gene fusions. This test is intended for the molecular evaluation of myeloid neoplasms, including myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), myelodysplastic/myeloproliferative neoplasms, and myeloid leukemias (AML) among others. The detection of molecular alterations described in these neoplasms can be useful in their diagnosis and classification. In addition, the pattern of particular alterations can be prognostically informative and can have implications for the use of both targeted and conventional therapies.

This NGS panel could serve to consolidate several single gene assays into a single test if indicated. Preset gene panels are available for order as well as individual genes. If a small number of genes are needed (1-3 single genes), we will continue to use the existing single gene tests where appropriate as we make this transition to the NGS panel. On the types of cases that this testing is currently being added to, performing the NGS myeloid panel in-house will decrease turn-around-time significantly compared to the current send out NGS panel.

Please refer to the Allina Health test catalog for collection and processing information.